Literature DB >> 7688820

Resistance of a human serum-selected human immunodeficiency virus type 1 escape mutant to neutralization by CD4 binding site monoclonal antibodies is conferred by a single amino acid change in gp120.

J A McKeating1, J Bennett, S Zolla-Pazner, M Schutten, S Ashelford, A L Brown, P Balfe.   

Abstract

We have selected an HXB2 variant which can replicate in the presence of a neutralizing human serum. Sequencing of the gp120 region of the env gene from the variant and parental viruses identified a single amino acid substitution in the third conserved region of gp120 at residue 375 (AGT-->AAT, Ser-->Asn; designated 375 S/N). The escape mutant was found to be resistant to neutralization by soluble CD4 (sCD4) and four monoclonal antibodies (MAbs), 39.13g, 1.5e, G13, and 448, binding to epitopes overlapping that of the CD4 binding site (CD4 b.s.). Introduction of the 375 S/N mutation into HXB2 by site-directed mutagenesis confirmed that this mutation is responsible for the neutralization-resistant phenotype. Both sCD4 and three of the CD4 b.s. MAbs (39.13g, 1.5e, and G13) demonstrated reduced binding to the native 375 S/N mutant gp120. The ability to select for an escape variant resistant to multiple independent CD4 b.s. MAbs by a human serum confirms the reports that antibodies to the discontinuous CD4 b.s. are a major component of the group-specific neutralizing activity in human sera.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7688820      PMCID: PMC237919     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  37 in total

1.  Evaluation of human and simian immunodeficiency virus plaque and neutralization assays.

Authors:  J A McKeating; A McKnight; K McIntosh; P R Clapham; C Mulder; R A Weiss
Journal:  J Gen Virol       Date:  1989-12       Impact factor: 3.891

2.  Characterization of HIV-1 neutralization escape mutants.

Authors:  J A McKeating; J Gow; J Goudsmit; L H Pearl; C Mulder; R A Weiss
Journal:  AIDS       Date:  1989-12       Impact factor: 4.177

3.  Generation of a neutralization-resistant variant of HIV-1 is due to selection for a point mutation in the envelope gene.

Authors:  M S Reitz; C Wilson; C Naugle; R C Gallo; M Robert-Guroff
Journal:  Cell       Date:  1988-07-01       Impact factor: 41.582

4.  Prevalence of antibodies to human immunodeficiency virus, gonorrhoea rates, and changed sexual behaviour in homosexual men in London.

Authors:  C A Carne; I V Weller; A M Johnson; C Loveday; F Pearce; A Hawkins; A Smith; P Williams; R S Tedder; M W Adler
Journal:  Lancet       Date:  1987-03-21       Impact factor: 79.321

5.  HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-related complex.

Authors:  M Robert-Guroff; M Brown; R C Gallo
Journal:  Nature       Date:  1985 Jul 4-10       Impact factor: 49.962

6.  An IgG human monoclonal antibody that reacts with HIV-1/GP120, inhibits virus binding to cells, and neutralizes infection.

Authors:  M R Posner; T Hideshima; T Cannon; M Mukherjee; K H Mayer; R A Byrn
Journal:  J Immunol       Date:  1991-06-15       Impact factor: 5.422

7.  Human immunodeficiency virus-infected individuals contain provirus in small numbers of peripheral mononuclear cells and at low copy numbers.

Authors:  P Simmonds; P Balfe; J F Peutherer; C A Ludlam; J O Bishop; A J Brown
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

8.  Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein.

Authors:  K Javaherian; A J Langlois; C McDanal; K L Ross; L I Eckler; C L Jellis; A T Profy; J R Rusche; D P Bolognesi; S D Putney
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

9.  Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees.

Authors:  J Goudsmit; C Debouck; R H Meloen; L Smit; M Bakker; D M Asher; A V Wolff; C J Gibbs; D C Gajdusek
Journal:  Proc Natl Acad Sci U S A       Date:  1988-06       Impact factor: 11.205

10.  Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120.

Authors:  J R Rusche; K Javaherian; C McDanal; J Petro; D L Lynn; R Grimaila; A Langlois; R C Gallo; L O Arthur; P J Fischinger
Journal:  Proc Natl Acad Sci U S A       Date:  1988-05       Impact factor: 11.205

View more
  16 in total

1.  Antigenic variation within the CD4 binding site of human immunodeficiency virus type 1 gp120: effects on chemokine receptor utilization.

Authors:  A L Hammond; J Lewis; J May; J Albert; P Balfe; J A McKeating
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

2.  Significant differences in cell-cell fusion and viral entry between strains revealed by scanning mutagenesis of the C-heptad repeat of HIV gp41.

Authors:  Barbara Diaz-Aguilar; Karen Dewispelaere; Hyun Ah Yi; Amy Jacobs
Journal:  Biochemistry       Date:  2013-05-07       Impact factor: 3.162

3.  Inhibition of HIV infectivity by a natural human isolate of Lactobacillus jensenii engineered to express functional two-domain CD4.

Authors:  Theresa L-Y Chang; Chia-Hwa Chang; David A Simpson; Qiang Xu; Patrick K Martin; Laurel A Lagenaur; Gary K Schoolnik; David D Ho; Sharon L Hillier; Mark Holodniy; John A Lewicki; Peter P Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-12       Impact factor: 11.205

4.  Antibodies of symptomatic human immunodeficiency virus type 1-infected individuals are directed to the V3 domain of noninfectious and not of infectious virions present in autologous serum.

Authors:  M Schreiber; H Petersen; C Wachsmuth; H Müller; F T Hufert; H Schmitz
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

Review 5.  The human immunodeficiency virus type 1 (HIV-1) CD4 receptor and its central role in promotion of HIV-1 infection.

Authors:  S Bour; R Geleziunas; M A Wainberg
Journal:  Microbiol Rev       Date:  1995-03

6.  Increased sensitivity to CD4 binding site-directed neutralization following in vitro propagation on primary lymphocytes of a neutralization-resistant human immunodeficiency virus IIIB strain isolated from an accidentally infected laboratory worker.

Authors:  Tim Beaumont; Esther Quakkelaar; Ad van Nuenen; Ralph Pantophlet; Hanneke Schuitemaker
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

7.  Engineering of a human vaginal Lactobacillus strain for surface expression of two-domain CD4 molecules.

Authors:  Xiaowen Liu; Laurel A Lagenaur; Peter P Lee; Qiang Xu
Journal:  Appl Environ Microbiol       Date:  2008-06-06       Impact factor: 4.792

8.  Neutralization profiles of primary human immunodeficiency virus type 1 isolates in the context of coreceptor usage.

Authors:  D Cecilia; V N KewalRamani; J O'Leary; B Volsky; P Nyambi; S Burda; S Xu; D R Littman; S Zolla-Pazner
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

9.  Human immunodeficiency virus type 1 evades T-helper responses by exploiting antibodies that suppress antigen processing.

Authors:  Peter C Chien; Sandra Cohen; Michael Tuen; James Arthos; Pei-de Chen; Sukeshi Patel; Catarina E Hioe
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

10.  Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals.

Authors:  C Moog; H J Fleury; I Pellegrin; A Kirn; A M Aubertin
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.